Receiving HER2-targeted therapy was associated with improved OS in multivariable Cox proportional hazards analysis in patients without gastric, GEJ, or esophageal cancers (hazard ratio, 0.50; 95% CI, 0.27 to 0.93). Here, ERBB2 is linked to esophageal cancer.